Want to see GB:STX full AI Analyst Report?
Total Valuation
Shield Therapeutics has a market cap or net worth of £65.78M. The enterprise value is 109.63M .
Market Cap£65.78M
Enterprise Value109.63M
Share Statistics
Shield Therapeutics has 1,069,524,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,069,524,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shield Therapeutics’s return on equity (ROE) is 1.20 and return on invested capital (ROIC) is -68.36%.
Return on Equity (ROE)1.20
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-68.36%
Return on Capital Employed (ROCE)-0.68
Revenue Per Employee831.86K
Profits Per Employee-295.50K
Employee Count61
Asset Turnover0.78
Inventory Turnover3.08
Valuation Ratios
The current PE Ratio of Shield Therapeutics is ―. Shield Therapeutics’s PEG ratio is 0.16.
PE Ratio―
PS Ratio1.71
PB Ratio-5.76
Price to Fair Value-5.76
Price to FCF-9.83
Price to Operating Cash Flow-4.56
PEG Ratio0.16
Income Statement
In the last 12 months, Shield Therapeutics had revenue of 50.74M and earned -18.03M in profits. Earnings per share was -0.02.
Revenue50.74M
Gross Profit22.38M
Operating Income-10.30M
Pretax Income-17.50M
Net Income-18.03M
EBITDA-9.16M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -19.16M and capital expenditures -24.13K, giving a free cash flow of -19.19M billion.
Operating Cash Flow-19.16M
Free Cash Flow-19.19M
Free Cash Flow per Share-0.02
Dividends & Yields
Shield Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.82
52-Week Price Change115.79%
50-Day Moving Average6.68
200-Day Moving Average8.46
Relative Strength Index (RSI)43.01
Average Volume (3m)3.16M
Important Dates
Shield Therapeutics upcoming earnings date is Sep 3, 2026, TBA (Confirmed).
Last Earnings DateApr 9, 2026
Next Earnings DateSep 3, 2026
Ex-Dividend Date―
Financial Position
Shield Therapeutics as a current ratio of 0.90, with Debt / Equity ratio of -199.87%
Current Ratio0.90
Quick Ratio0.72
Debt to Market Cap0.35
Net Debt to EBITDA-2.02
Interest Coverage Ratio-1.36
Taxes
In the past 12 months, Shield Therapeutics has paid 524.78K in taxes.
Income Tax524.78K
Effective Tax Rate-0.03
Enterprise Valuation
Shield Therapeutics EV to EBITDA ratio is -11.50, with an EV/FCF ratio of -11.93.
EV to Sales2.08
EV to EBITDA-11.50
EV to Free Cash Flow-11.93
EV to Operating Cash Flow-11.96
Balance Sheet
Shield Therapeutics has £11.63M in cash and marketable securities with £30.15M in debt, giving a net cash position of -£18.52M billion.
Cash & Marketable Securities£11.63M
Total Debt£30.15M
Net Cash-£18.52M
Net Cash Per Share-£0.02
Tangible Book Value Per Share-£0.04
Margins
Gross margin is 44.16%, with operating margin of -20.29%, and net profit margin of -35.52%.
Gross Margin44.16%
Operating Margin-20.29%
Pretax Margin-34.49%
Net Profit Margin-35.52%
EBITDA Margin-18.05%
EBIT Margin-20.29%
Analyst Forecast
The average price target for Shield Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast49.81%
EPS Growth Forecast52.94%